Genentech

#Breaking: We are presenting data across our Alzheimer’s disease portfolio at #AAIC2026, highlighting our dedication to detect, slow and hopefully one day prevent this devastating disease. Learn more: gene.com/media/press-re…

#Breaking: New positive Phase III results demonstrate superiority of an investigational molecule over standard-of-care KRAS G12C inhibitors in the first global head-to-head study in KRAS G12C-mutant non-small cell lung cancer: gene.com/media/press-re…

#Breaking: The @US_FDA has granted priority review for our treatment for thyroid eye disease (TED), an autoimmune disease that can lead to facial disfigurement and vision threatening complications if left untreated. Learn more: gene.com/media/press-re…

#Breaking: @US_FDA accepted the supplemental Biologics License Application (sBLA) supporting a combination treatment for people living with relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma: gene.com/media/press-re…

#Breaking: @US_FDA accepted our supplemental Biologics License Application (sBLA) and granted Priority Review for an investigational adjuvant combination regimen in a certain type of stage III colon cancer: gene.com/media/press-re…

#Breaking: @US_FDA accepted the New Drug Application, under Priority Review, for our investigational oral selective estrogen receptor degrader (SERD) as a treatment for adults with ER+, HER2-, early-stage breast cancer. Learn more: gene.com/media/press-re…

#Breaking: We are presenting data at the upcoming #ADASciSessions from our obesity portfolio, highlighting our differentiated approaches to addressing unmet needs for people living with #obesity. Learn more: gene.com/media/press-re…

#Breaking: We’re presenting new data across breast, lung, gastrointestinal, bladder and blood cancers at the American Society of Clinical Oncology (#ASCO26). Learn more about our efforts to transform cancer care: gene.com/media/press-re…

#Breaking: @US_FDA approved our immunotherapy as an adjuvant treatment option for adults with muscle-invasive bladder cancer (#MIBC) after surgery (cystectomy) who have circulating tumor DNA (ctDNA) molecular residual disease. Learn more: gene.com/media/press-re…

At the Association for Research in Vision and Ophthalmology Annual Meeting, we’re sharing key real-world, product and pipeline data from our ophthalmology portfolio. Learn more: gene.com/media/press-re… #ARVO2026

Launching today, All Eyes on DME is our new campaign highlighting diabetic macular edema (DME), an often overlooked eye condition linked to diabetes. Learn more: gene.com/media/press-re…

#Breaking: At the 2026 AAN Annual Meeting (#AANAM), we unveiled positive comprehensive results from our Phase III trials evaluating our investigational BTK inhibitor (BTKi) in people living with relapsing multiple sclerosis (RMS). Learn more: gene.com/media/press-re…

#Breaking: At #AANAM, we announced positive results from our Phase III study in myelin oligodendrocyte glycoprotein antibody disease (MOGAD). Learn more: gene.com/media/press-re…

#Breaking: The @US_FDA accepted our supplemental Biologics License Application for our medicine to treat systemic lupus erythematosus (SLE), the most common form of #lupus, based on positive Phase III data. If approved, it would be the first therapy to directly target B cells in SLE. Learn more: [gene.com/media/press-re…]

#Breaking: Today meaningful data from our Phase III study in systemic lupus erythematosus was published in @NEJM. Learn more: gene.com/media/press-re…

#Breaking: Positive Phase II results for our investigational long‑acting amylin analog with Zealand Pharma mark an important step forward as we move from a one‑size‑fits‑all approach to more tailored options for people living with #obesity. gene.com/media/press-re…

#Breaking: Today we announced positive additional Phase III clinical results of our investigational BTK inhibitor in people living with relapsing multiple sclerosis (RMS). Learn more: gene.com/media/press-re…

#Breaking: @US_FDA approved our new combination regimen as the first and only all-oral, fixed-duration treatment for previously untreated adults with chronic lymphocytic leukemia (CLL). Learn more: gene.com/media/press-re…

#Breaking: @US_FDA accepts New Drug Application for our investigational oral therapy in ER+ advanced #BreastCancer. Learn more: gene.com/media/press-re…

#Breaking: Today we announced positive Phase III data in primary membranous nephropathy. Learn more: gene.com/media/press-re…